hBD-1 vs PACAP-38
Head-to-head comparison of hBD-1 (Human beta-defensin 1) and PACAP-38 (Pituitary Adenylate Cyclase-Activating Polypeptide-38 (human PACAP-38)) — benefits, dosing, side effects, research data, and where to buy.
| Property | hBD-1 | PACAP-38 |
|---|---|---|
| Category | Dental & Oral | Cognitive Enhancement |
| Full Name | Human beta-defensin 1 | Pituitary Adenylate Cyclase-Activating Polypeptide-38 (human PACAP-38) |
| Molecular Weight | 4490 Da | 4534 Da |
| Half-Life | minutes to hours | minutes |
| Amino Acids | 36 | 38 aa |
| Typical Dose | 1-10 µg/mL in experimental studies | 10-100 µg preclinical range |
| Route | Topical/Intraoral | Intranasal |
| Purity | ≥98% | ≥98% |
| Studies Count | 85 | 650 |
| Research Status | Pre-clinical | Pre-clinical |
hBD-1 Benefits
- ✓oral innate immunity
- ✓broad antimicrobial activity
- ✓biofilm suppression
- ✓periodontal support
PACAP-38 Benefits
- ✓synaptic plasticity
- ✓BDNF upregulation
- ✓neuroprotection
- ✓memory consolidation
hBD-1 Dosing
topical peptide exposure|cell-culture or mucosal models|repeat low-dose application in research
PACAP-38 Dosing
0.1-1 nmol ICV in rodents|10-100 µg intranasal in preclinical studies|single-dose or short repeated protocols
hBD-1 Side Effects
- ⚠protease degradation
- ⚠local irritation at high dose
- ⚠limited stability in saliva
PACAP-38 Side Effects
- ⚠headache-like effects
- ⚠flushing
- ⚠hypotension
Research Overview
hBD-1
hBD-1 has been studied as part of the oral mucosal defense system and is linked to host resistance against dental pathogens. Research spans periodontitis, candidiasis, and epithelial barrier biology.
PACAP-38
PACAP-38 is one of the most studied endogenous neuropeptides for protecting neurons from ischemic and excitotoxic damage. Preclinical literature also links it to hippocampal plasticity and learning-related signaling, including increased BDNF expression.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.